Nicholas Boulis

Nicholas Boulis

Nicholas Boulis

Associate Professor
MD
Director, Gene and Cell Therapy for Neurorestoration Laboratory

Dr. Nicholas M. Boulis is a neurosurgeon in Atlanta, Georgia and is affiliated with multiple hospitals in the area, including Emory University Hospital Midtown and Grady Memorial Hospital. He received his medical degree from Harvard Medical School and has been in practice for more than 20 years.

nicholas.boulis@emoryhealthcare.org

404-778-5770

Office Location:
Emory Clinic, Building B

Website

  • Related Site
  • Google Scholar

    University, College, and School/Department
    Research Focus Areas:
    • Chemical Biology
    • Neuroscience
    • Regenerative Medicine
    Additional Research:
    Boulis is a functional neurosurgeon with significant expertise in the field of gene transfer to the nervous system. Dr. Boulis' Gene and Cell Therapy Translational Laboratory pursues advanced biological treatments for neurological disorders, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease) and Spinal Muscular Atrophy (SMA).

    IRI Connections:

    Robert Gross

    Robert Gross

    Robert Gross

    MBNA Bowman Chair & Professor
    Director and Co-Founder, ENTICe
    Director, Translational Neuro-Engineering Laboratory
    Director, Stereotactic, Functional Neurosurgery & Epilespsy Surgery

    Dr. Gross’s research interests include: restorative approaches (including cell and gene therapy) for Parkinson's disease and other neurodegenerative disorders; physiology of movement disorders (Parkinson's disease, tremor, dystonia); novel surgical techniques for epilepsy (e.g. deep brain stimulation, cell and gene therapy). In particular, he has been elucidating the role of axon guidance molecules in the development and reconstruction of the nigrostriatal pathway, which degenerates in P.D. This approach, which encompasses molecular and cellular engineering in combination with neurotransplantation, may be generally useful in reconstructive approaches for many types of nervous system degeneration and injury. 

    In July of 2007, Dr. Gross, along with Steve M. Potter, Ph.D. of the Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, was the recipient of a prestigious grant from The Epilepsy Research Foundation (ERF) for translational research funding awards supporting innovative epilepsy products. The grant supports the development of a novel electrical stimulation approach that directly controls the activity of the brain to attain a more stable state from which seizures will not arise.

    rgross@emory.edu

    404-727-2354

    Office Location:
    Emory WMRB 6311

    Website

  • Related Site
  • Google Scholar

    University, College, and School/Department
    Research Focus Areas:
    • Neuroscience
    • Regenerative Medicine
    Additional Research:
    Neuromodulation using multielecrode arrays, closed loop control theory, and optogenetics for epilepsy and movement disorders. Computational modeling of epilepsy networks for model-based and non-model based feedback control of optogenetic and electrical neuromodulation. Neurorestoration using gene and cell-therapy based approaches for degenerative and injury conditions. The Translational Neuroengineering Research Lab uses neuromodulation for epilepsy using a combination of the following advanced techniques: 1) Multimicroelectrode electrical stimulation using novel parameters informed by optimization of input/output relationships (both model- and non-model based MIMO) using closed-loop control theory including adaptive learning and machine learning approaches; 2) Optogenetic activation and inhibition using all forms of available channels including step-function opsins. These approaches identify novel brain regions that have more widespread control and targets specific cell types for activation and inhibiton. Closed loop control using multielecrode arrays informs and controls neuromodulation. 3) Hardware independent 'luminopsins': novel gene therapy approaches combining bioluminescent proteins with optogenetic channels for hardware independent, widespread and activity-regulatable neuromodulation. We use a combination of in vitro models, animal models (mouse, rat, non-human primate) and human patients undergoing epilepsy and deep brain stimulation surgery as our experimental models. In addition, the laboratory has developed novel gene therapy vectors for neurorestoration targeting key pivotal proteins regulating axon outgrowth in regenerative situations, including for Parkinson's disease, spinal cord injury and retinal degeneration.

    IRI Connections: